Home›Acamprosate Calcium

Acamprosate Calcium

Also known as: Acamprosate Calcium

Route: Oral

Check Acamprosate Calcium Interactions →

4 interactions on record

Acamprosate Calcium has 4 known drug interactions based on U.S. FDA drug labeling data. Patients taking Acamprosate Calcium should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 4
Minor: 4

Minor (4)

Acamprosate Calcium + Alcohol— Acamprosate does not affect the pharmacokinetics of alcohol, and alcohol does not affect acamprosate pharmacokinetics.
Acamprosate Calcium + Diazepam— Diazepam does not affect the pharmacokinetics of acamprosate; no clinically important interaction.
Acamprosate Calcium + Disulfiram— Disulfiram does not affect the pharmacokinetics of acamprosate; no clinically important interaction.
Acamprosate Calcium + Naltrexone— Clinically important interactions between naltrexone and acamprosate were not observed.

Acamprosate Calcium + Alcohol🟢Minor

Acamprosate does not affect the pharmacokinetics of alcohol, and alcohol does not affect acamprosate pharmacokinetics.

Acamprosate Calcium + Diazepam🟢Minor

Diazepam does not affect the pharmacokinetics of acamprosate; no clinically important interaction.

Acamprosate Calcium + Disulfiram🟢Minor

Disulfiram does not affect the pharmacokinetics of acamprosate; no clinically important interaction.

Acamprosate Calcium + Naltrexone🟢Minor

Clinically important interactions between naltrexone and acamprosate were not observed.

Contraindications

4 CONTRAINDICATIONS Acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components ( 4.1 ). Acamprosate calcium is contraindicated in patients with severe renal impairment ( 4.2 ). 4.1 Hypersensitivity to Acamprosate Calcium Acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components. 4.2 Severe Renal Impairment Acamprosate calcium is contraindicated in patients with severe renal impairment (creatinine clearance of ≤30 mL/min) [ see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ].

Pregnancy & Breastfeeding

8.1 Pregnancy Teratogenic effects: Acamprosate calcium has been shown to be teratogenic in rats when given in doses that are approximately equal to the human dose (on a mg/m 2 basis) and in rabbits when given in doses that are approximately 3 times the human dose (on a mg/m 2 basis). Acamprosate calcium produced a dose-related increase in the number of fetuses with malformations in rats at oral doses of 300 mg/kg/day or greater (approximately equal to the maximum recommended human daily (MRHD) oral dose on a mg/m 2 basis). The malformations included hydronephrosis, malformed iris, retinal dysplasia, and retroesophageal subclavian artery. No findings were observed at an oral dose of 50 mg/kg/day (approximately one-fifth the MRHD oral dose on a mg/m 2 basis). An increased incidence of hydronephrosis was also noted in Burgundy Tawny rabbits at oral doses of 400 mg/kg/day or greater (approximately 3 times the MRHD oral dose on a mg/m 2 basis). No developmental effects were observed in New Zealand white rabbits at oral doses up to 1000 mg/kg/day (approximately 8 times the MRHD oral dose on a mg/m 2 basis). The findings in animals should be considered in relation to known adverse developmental effects of ethyl alcohol, which include the characteristics of fetal alcohol syndrome (craniofacial dysmorphism, intrauterine and postnatal growth retardation, retarded psychomotor and intellectual development) and milder forms of neurological and behavioral disorders in humans. There are no adequate and well controlled studies in pregnant women. Acamprosate calcium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic effects: A study conducted in pregnant mice that were administered acamprosate calcium by the oral route starting on Day 15 of gestation through the end of lactation on postnatal day 28 demonstrated an increased incidence of still-born fetuses at doses of 960 mg/kg/day or greater (approximately 2 times

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.